<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986424</url>
  </required_header>
  <id_info>
    <org_study_id>M900011005</org_study_id>
    <nct_id>NCT03986424</nct_id>
  </id_info>
  <brief_title>Local Study of Akatinol Memantine in VaD in Russia</brief_title>
  <acronym>MIND</acronym>
  <official_title>Multi-center Open Comparative Randomized Study of Efficacy and Safety of Akatinol Memantine 20 mg (Single-doses) vs. Akatinol Memantine 10 mg (Double-doses) in Patients With Moderate and Moderately Severe Vascular Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LLC Merz Pharma, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the clinical efficacy and safety of Akatinol Memantine 20 mg
      (single-doses) vs. Akatinol Memantine 10 mg (double-doses) in patients suffering from
      moderate and moderately severe vascular dementia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 23, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in total ADAS-cog score points</measure>
    <time_frame>24 weeks</time_frame>
    <description>ADAS-cog - Alzheimer's Disease Assessment scale, cognitive subscale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>Akatinol Memantine 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Akatinol Memantine 20 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Akatinol Memantine 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Akatinol Memantine 10 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Akatinol Memantine 20 mg</intervention_name>
    <description>Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day</description>
    <arm_group_label>Akatinol Memantine 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Akatinol Memantine 10 mg</intervention_name>
    <description>Akatinol Memantine 10 mg to be taken orally, twice daily</description>
    <arm_group_label>Akatinol Memantine 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from the patient or his/her legal representative if
             the patient is declared incapable by a court decision.

          -  Understanding of study procedures and willingness to abide to all procedures during
             the course of the study by the patient or his/her legal representative.

          -  Male and female patients from 50 to 85 years of age (inclusive) suffering from
             moderate and moderately severe vascular dementia.

          -  Mini-Mental State Examination (MMSE) Test total scores of 10 to 20.

          -  Hachinski's Ischemic Score (HIS) of 7 or higher point.

          -  Availability in the anamnesis of instrumental confirmation of the diagnosis (data
             methods of neurovisualization - CT or MRT).

          -  For females: menopause or inability to conceive due to other reasons (hysterectomy,
             etc.).

          -  Availability of a relative or legal representative who lives with the patient,
             monitors him/her and cares for the patient.

        Exclusion Criteria:

          -  Alzheimer's disease or secondary types of dementia.

          -  Epilepsy, seizures, schizophrenia, other psychoses, bipolar disorder, alcoholism, drug
             abuse (including the history thereof).

          -  Other clinically significant neurological or psychiatric disorders.

          -  Severe depression (Hamilton score, HAM-D &gt; 18 points).

          -  Severe, unstable or decompensated physical disease (including clinically significant
             laboratory abnormalities) potentially affecting the trial findings.

          -  Contraindications to oral drug intake during the time period determined by the study
             protocol.

          -  Known hypersensitivity to the investigational product or any of its ingredients.

          -  Administration of nootropic, anti-dementia and typical antipsychotic drugs, tricyclic
             antidepressants, long-acting benzodiazepines, NMDA receptor antagonists (amantadine,
             ketamine, dextromethorphan) for 1 month before the enrollment and during the study.

          -  For females: pregnancy and breastfeeding.

          -  Evidence or suspicion that the patient might not comply with the study directive.

          -  Any reason or contraindication which in the investigator's opinion precludes
             participation in the study.

          -  Patient is direct relative of an employee of the study site or Merz Pharma LLC.

          -  Previous participation in this clinical study.

          -  Participation in another clinical trial within the last 12 weeks prior to screening or
             ongoing participation in a study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Russia Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Russia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal State Budgetary Scientific Institution &quot;Mental Health Research Center&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Autonomous Institution of Higher Learning &quot;Peoples' Friendship University of Russia&quot;, Medical Institute</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal state budgetary military educational institution of higher education &quot;Military Medical Academy named after S.M. Kirov&quot; of the Ministry of defence of the Russian Federation</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

